Ann Hynes

Management said Chinese competition is mostly in early-stage chemistry and biology, not regulated safety assessment; watching closely but sees limited regulated-work migration.

Girshick said both major client segments are strengthening; global biopharma has moved through restructuring and has been booking more work over the last 18 months.

Birgit confirmed $300M cumulative savings (~5% of cost base), with $100M incremental in 2026, but declined to provide 2027-2028 specifics until Investor Day. On AI insourcing risk, she firmly stated pharma lacks capacity and skill set for preclinical work, and any in-sourcing trend would be limited to early discovery or clinical, not regulated safety assessment.

Foster said biotech funding typically takes a couple quarters to convert to revenue as clients are judicious with new capital. Capacity utilization is below optimal low-80s level but provides flexibility to accommodate demand recovery without 18-24 month build times.

Pease said pricing improved slightly in Q1 driven by favorable mix from specialty studies; current environment much better than 2008-09 given better capacity management and more outsourcing.

Foster deferred providing updated long-term growth rates, saying they need to refresh financial goals and will address at a future Investor Day.

James differentiated from 2009-2012 downturn: thousands more biotech companies, pharma leaner, less excess capacity. Expressed conviction in pent-up demand and powerful drug modalities.

James described modest improvement in biotech embedded in guidance, driven by improving capital markets and venture inflows, but insufficient to offset stable-to-flat pharma.

Hazen gave bed counts, occupancy trend and outpatient site additions, and directly addressed share position and demographic support for the investment.

Mike expressed optimism about Florida DPP prospects and noted additional revenues may be significant if approved. Provided detailed exchange payer mix analysis.

Mike confirmed exchange patient amounts due are growing with shift from silver to bronze plans, but impact is manageable given small share of total collections.

Mike detailed four resiliency pillars plus three capabilities (benchmarking, digital/AI transformation, shared service platforms). Exchange model: 15-20% HICS volume decline, 15-20% migrate to ESI, remainder uninsured with 30% utilization decline.

Mike identified Florida, Georgia, and Virginia as pending grandfathered applications. Reviews continue during government shutdown. Declined to size potential impact until approved. Updated guidance excludes any additional approvals.

Mike outlined three resiliency categories: benchmarking, automation/digital transformation, and shared services. Will provide detailed sizing on Q4 2025 call with 2026 guidance. Near-term act impacts expected offset by resiliency.

Mike confirmed guidance reiteration is straightforward with no assumption changes. Detailed outpatient surgery dynamics: revenue grew faster than inpatient, case declines driven by lower acuity and Medicaid.

Mike quantified the Two-Midnight Rule benefit precisely and noted MA observation is approximately 20% higher than traditional Medicare. Does not expect material change in 2025.

Gave the sequential direction ahead of the 10-Q and explained why flat reserves are conservative given pharmacy claim processing speed.

Celeste confirmed IBNR intentionally set well above membership growth as prudent reserving given early-year uncertainty. Reiterated all early indicators and completed claims through April running in line to better than expectations.

Celeste said biggest difference is embedded conservatism plus a broader haircut on known headwinds/tailwinds. Cost trends similar to 2025: higher end of mid-single-digit medical and low double-digit Rx, but slightly higher due to doc fix timing.

James outlined portfolio approach to contracts. Moving members to 4/4.5 star contracts. Good progress in first 2 weeks of AEP. Will take 2-3 cycles to fully accomplish.

Celeste detailed better CenterWell patient growth, pharmacy revenue, and membership. Medicaid running in line. George explained HUM's Medicaid resilience: LTSS focus, favorable state footprints, value-based network structure.

George confirmed V28 phased over three years, exactly in line with original estimates. 160bps is HUM-specific vs CMS industry estimate.

Celeste provided clear puts and takes on the benefit ratio: plan exits, benefit adjustments, calendar as positives; Medicaid mix, IRA impact, incremental investments as negatives. Left specific modeling to analysts.

London gave an extended qualitative framework on scope, impactability and rate tools, and committed to margin progression, but declined to quantify 2027 margin direction.

Drew acknowledged December 2027 and summer 2028 maturities, planning to refinance or partially pay down roughly a year ahead. Cash position improved materially in last 6-12 months from PDP receivable sale and strong operations. Evaluating right debt load given business volatility, potentially opening other capital deployment avenues.

Sarah noted 2025 rates matured favorably from lower start to 5.5% composite, suggesting similar dynamic possible in 2026. Emphasized two full years of acuity and trend data now informing rate decisions, plus trend-bending execution in back half of 2025 balancing the rate assumption.

Drew detailed: Medicare high single-digit to 10%+ trend continuing, marketplace mid-30s composite with risk pool shift more important than trend, Medicaid jumping off 94.2% 1H with mid-5s rates annualizing plus multiple drug carve-outs and ABA task force progress.

Sarah noted coding intensity likely concentrated at larger hospital systems with sophisticated revenue cycle operations. CNC investing in AI-driven payment integrity to match provider-side AI revenue cycle optimization.

Sarah confirmed full-year composite at mid-4s. Beyond flu, behavioral health continues as trend item, pockets of home health, and high-cost drugs like Lenmeldy ($3.2M/treatment).

Mark gave qualitative color on Medicaid utilization/acuity and said ACA trend was in line to slightly favorable, but did not provide division-level trend figures.

Mark confirmed Q1 sequential margin deterioration came in as expected, maintaining -1.75% operating margin guide. Felicia noted Medicaid rates tracking mid-single-digit, slightly below trend, with constructive state discussions.

Mark clarified line-of-business margins unchanged but segment margin recalibrated for portfolio mix: ACA now larger share relative to group commercial. Pete explained CarelonRx margin adjustment reflects growth diversification into large upmarket jumbo accounts and specialty pharmacy, both carrying different profiles.

Mark confirmed 2026 average Medicaid membership expected modestly lower than year-end 2025 with some stabilization in certain markets. Pete acknowledged Elevance membership impacts on Carelon but characterized as time-bound given strong external diversification momentum.

Gail differentiated between IDR abuse (legal action filed) and isolated AI-enabled coding inflating documentation acuity. Using analytics to identify aberrant patterns and putting through payment integrity process.

Mark confirmed comfort with trends but did not quantify the specific embedded Medicare trend growth rate, instead pointing to stable margins from retention and cost management.

Bobby Hunter declined specific membership guidance until later in the year but said the competitive landscape offers an opportunity to grow.

Noel confirmed trend is below planning assumptions but deferred the specific revised point estimate to the next call, leaving the question partly unanswered.

Sandeep outlined $1.5B AI spend split: 1/3 into Optum Insight AI-first products, 2/3 across enterprise processes. Expects conservative 2:1 return. Cited digital prior auth with 96% first-submission approval, Optum Real at 0.5B transactions, Optum AI consulting. Did not give specific SG&A savings targets.

Noel confirmed 10% is Medicare-specific assumption for 2026. 2025 closed at 7.5% in line with reset expectations. Commercial trend approximately 11%. Medicaid not as instructive for point estimate but similar themes of elevated trend persisting from early 2025 into 2026.

View unchanged from prior quarter. Expects breakeven in 2025 and margin degradation in 2026 as trough year driven by specialty pharmacy, behavioral health and home health. Over time about 18 to 24 months expected to return to rate margins of around 2%. One Big Beautiful Bill may drive some transformation with state collaboration.

Non-dual core Medicaid at breakeven in 2025 with 2026 expected at negative 1-1.7% margins. Rated margin target of 2% for Medicaid and 2-4% blended for community and state. Commercial pricing for double-digit increases. Medicaid premium increases running about 6% in 2025 with comparable expected in 2026.